Search | Clinical Trials Finder

Conditions: Anesthesia, Local, Prolapse, Prolapse; Female, Prolapse, Vaginal, Prolapse; Vagina, Posthysterectomy, Pain, Postoperative
Interventions: TAP block; Procedure
Lead sponsor: ProMedica Health System; Other
Eligibility: 18 Years and older · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Toledo, Ohio

Conditions: Ovarian Cancer, Fibroids, Uterine Cancer
Interventions: Bupivacaine, Liposomal bupivacaine; Drug
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Orange, California

Conditions: Uterine Fibroids, Endometriosis
Interventions: Relugolix Combination Tablet; Drug
Lead sponsor: Sumitomo Pharma Switzerland GmbH; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 120
States / cities: Mobile, Alabama • Chandler, Arizona • Mesa, Arizona + 98 more

Conditions: Adenovirus, Anesthesia, Anxiety, Anxiolysis, Autism, Autistic Disorder, Bacterial Meningitis, Bacterial Septicemia, Benzodiazepine, Bipolar Disorder, Bone and Joint Infections, Central Nervous System Infections, Convulsions, Cytomegalovirus Retinitis, Early-onset Schizophrenia Spectrum Disorders, Epilepsy, General Anesthesia, Gynecologic Infections, Herpes Simplex Virus, Infantile Hemangioma, Infection, Inflammation, Inflammatory Conditions, Intra-abdominal Infections, Lower Respiratory Tract Infections, Migraines, Pain, Pneumonia, Schizophrenia, Sedation, Seizures, Skeletal Muscle Spasms, Skin and Skin-structure Infections, Treatment-resistant Schizophrenia, Urinary Tract Infections, Withdrawal, Sepsis, Gram-negative Infection, Bradycardia, Cardiac Arrest, Cardiac Arrhythmia, Staphylococcal Infections, Nosocomial Pneumonia, Neuromuscular Blockade, Methicillin Resistant Staphylococcus Aureus, Endocarditis, Neutropenia, Headache, Fibrinolytic Bleeding, Pulmonary Arterial Hypertension, CMV Retinitis, Hypertension, Chronic Kidney Diseases, Hyperaldosteronism, Hypokalemia, Heart Failure, Hemophilia, Heavy Menstrual Bleeding, Insomnia
Interventions: The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:; Drug
Lead sponsor: Daniel Benjamin; Other
Eligibility: Up to 21 Years
Enrollment: 3,520 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 43
States / cities: Anchorage, Alaska • Little Rock, Arkansas • La Jolla, California + 37 more

Conditions: Ovarian Neoplasms, Endometriosis, Pelvic Pain, Uterine Neoplasms
Interventions: Chinese Acupuncture; Procedure
Lead sponsor: National Center for Complementary and Integrative Health (NCCIH); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Postoperative Pain After Uterine Fibroid Embolization, Uterine Fibroids (UF), Uterine Fibroids, Pelvic Pain, Pain Management
Interventions: TUNES (Transmucosal Uterosacral Electrical Stimulation), Sham TUNES Device; Device
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 28 Years to 52 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Endometriosis
Interventions: BAY1817080, Elagolix, Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 215 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 47
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 36 more

Conditions: Pelvic Pain
Interventions: Relugolix (40 mg) /estradiol (1 mg)/norethisterone acetate (0.5 mg) oral tablet; Drug
Lead sponsor: Endeavor Health; Other
Eligibility: 18 Years to 35 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Evanston, Illinois

Conditions: Metrorrhagia, Menorrhagia, Leiomyoma, Adenomyosis, Pelvic Pain, Endometriosis, Pelvic Inflammatory Disease
Interventions: Laparoscopic hysterectomy, Abdominal hysterectomy; Procedure
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Menstrual Migraines, Menstrual Bleeding, Menstrual Spotting
Interventions: Estradiol or Placebo; Drug
Lead sponsor: Scott and White Hospital & Clinic; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Temple, Texas

Conditions: Symptomatic Uterine Leiomyomas, Fibroids, Uterine Fibroids, Myomas
Interventions: Focused ultrasound (MRgFUS), Uterine artery embolization (UAE); Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 25 Years and older · Female only
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 3
States / cities: San Francisco, California • Rochester, Minnesota • Durham, North Carolina

Conditions: Uterine Fibroids, Adenomyosis
Interventions: Triamcinolone, Bupivacaine, Iohexol contrast; Drug · Other
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 30 Years to 60 Years · Female only
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 2
States / cities: Westwood, Los Angeles, California • Chapel Hill, North Carolina

Conditions: Symptomatic Uterine Fibroids and Adenomyosis
Interventions: IV Ibuprofen, IV Acetaminophen, Intravenous placebo/Intravenous placebo; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 21 Years to 60 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 2
States / cities: Los Angeles, California • Santa Monica, California

Conditions: Prolapse, Vaginal, Stress Urinary Incontinence, Pessaries, Pain
Interventions: Perineal massage; Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older · Female only
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Raleigh, North Carolina

Conditions: Dysmenorrhea, Menstrual Pain
Interventions: Sildenafil citrate vaginal suppository, Placebo vaginal suppository; Drug
Lead sponsor: Kevin Hellman; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Evanston, Illinois

Conditions: Dysmenorrhea (Disorder), Dysmenorrhea Primary, Dysmenorrhea Secondary, Endometrial Diseases, Leiomyoma, Fibroid Uterus
Interventions: Naproxen Sodium; Drug
Lead sponsor: Endeavor Health; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 183 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Evanston, Illinois

Conditions: Abortion, Spontaneous, Abortion in First Trimester, Pain Uterus, Abortion Early, Abortion, Missed
Interventions: 40cc buffered 0.5% lidocaine with 2 units of vasopressin paracervical block, 20cc 1% lidocaine with 2 units of vasopressin paracervical block; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older · Female only
Enrollment: 114 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 2
States / cities: La Jolla, California • San Diego, California

Conditions: Anxiety Disorder, Depression, Fatigue, Leydig Cell Tumor, Ovarian Sarcoma, Ovarian Stromal Cancer, Pain, Peritoneal Carcinomatosis, Pseudomyxoma Peritonei, Recurrent Breast Cancer, Recurrent Cervical Cancer, Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Cancer, Recurrent Gestational Trophoblastic Tumor, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Recurrent Primary Peritoneal Cavity Cancer, Recurrent Uterine Sarcoma, Recurrent Vaginal Cancer, Recurrent Vulvar Cancer
Interventions: questionnaire administration, quality-of-life assessment, psychosocial assessment and care, behavioral intervention, cognitive intervention, educational intervention; Other · Procedure · Behavioral
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 21 Years to 85 Years · Female only
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Pain Uterus
Interventions: Fentanyl, placebo; Drug
Lead sponsor: University of Hawaii; Other
Eligibility: 14 Years and older · Female only
Enrollment: 107 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 2
States / cities: Honolulu, Hawaii • Portland, Oregon

Conditions: Minimally Invasive Surgical Procedures, Abnormal Uterine Bleeding, Unspecified, Adenomyosis of Uterus, Fibroid Uterus, Chronic Pelvic Pain, Endometriosis, Menorrhagia, Endometritis, Adnexal Diseases
Interventions: Cyclobenzaprine; Drug
Lead sponsor: Christiana Care Health Services; Other
Eligibility: 18 Years and older · Female only
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Newark, Delaware

Conditions: Postpartum Period, Depression, Stress Disorders, Post-Traumatic
Interventions: Not listed
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older · Female only
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Pain, Bladder Cancer, Breast Cancer, CNS Cancer, Colon Cancer, Esophageal Cancer, Pancreatic Cancer, Prostate Cancer, Uterine Cancer, Head and Neck Cancer, Eye Cancer, Otorhinolaryngologic Neoplasms
Interventions: D-methadone, placebo; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: New York, New York

Conditions: Pain
Interventions: EMLA Cream, VersaPro Cream Base for Compounding; Drug
Lead sponsor: CAMC Health System; Other
Eligibility: 18 Years and older · Female only
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Charleston, West Virginia

Conditions: Gynecologic Cancer
Interventions: Single digit pelvic exam; Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: St Louis, Missouri

Search by objective public record fields.

Tap Block vs Conventional Pain Medication for Patients Undergoing Robotic Sacrocolpopexy

Pilot Study of Liposomal Bupivacaine Redosing in Patients Undergoing Major Gynecologic Procedures

A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis

Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care

Acupuncture for Women's Health Conditions

Transmucosal Uterosacral Electrical Stimulation for Pelvic Pain Relief

Study to Gather Information How Well Three Different Doses of BAY1817080 Given Twice Daily Over 12 Weeks Work in Comparison to an Inactive Pill (Placebo) and Elagolix in Women Suffering From Pain Related to a Condition Where the Tissue That Usually Grows Inside the Womb Grows Outside of the Womb

Phenotyping of Idiopathic Pelvic Pain With Real-time Uterine Imaging and Relugolix-Combination Therapy Treatment

Surgical Success After Laparoscopic vs Abdominal Hysterectomy

Prevention of Menstrual Migraines: Effects of Estrogen Add-back During the HFI in Patients Using Continuous Oral Contraceptives.

The FIRSTT: Comparing MRgFUS(MR-guided Focused Ultrasound) Versus UAE (Uterine Artery Embolization)for Uterine Fibroids.

Effect of Addition of Steroids on Duration of Analgesia

Effectiveness of IV Acetaminophen and IV Ibuprofen in Reducing Post Procedural Pain in the UFE Procedure

Perineal Massage for Pessary Examinations

Vaginal Sildenafil for Primary Dysmenorrhea

Mechanistic Characterization of Uterine Pain

Effect of Paracervical Block Volume on Pain Control for Dilation and Curettage.o

Stress Reduction in Improving Quality of Life in Patients With Recurrent Gynecologic or Breast Cancer

Intranasal Fentanyl for Pain Control During First-Trimester Uterine Aspiration

Cyclobenzaprine for Postoperative Pain in Minimally Invasive Hysterectomy

Relationship Between Postpartum Mood Disorders and Delivery Experience

Study of D-Methadone in Patients With Chronic Pain

EMLA Cream as Analgesic for Outpatient Gynecological Procedures

Identification and Prevention of Pelvic Floor Dysfunction in Gynecologic Cancer Survivors